Zeynep İNCE, Özgül BULUT, Melike TUĞRUL AKSAKAL, Ayşegül ÜNÜVAR, Ömer DEVECİOĞLU, Asuman ÇOBAN

Asymptomatic intracranial hemorrhage in a newborn with congenital factor VII deficiency and successful treatment with recombinant activated factor VII

Intracranial hemorrhage is considered the most common cause of death innewborns with congenital factor VII (FVII) deficiency. Recombinant activatedFVII (rFVIIa) provides specific replacement therapy, however there is limitedexperience with its neonatal use. We describe our experience about thetreatment of intracranial hemorrhage in a newborn with congenital FVIIdeficiency and emphasize the importance of imaging in asymptomatic patients.She presented with ecchymoses on her skin, no other pathological clinical signs,prolonged PT, normal PTT and FVII activity of 2%. Intracranial hemorrhagewas diagnosed while screening for internal bleedings. Treatment with rFVIIaresulted in stabilization and regression of the hematoma.

PDF

___

1. Farah RA, Hamod D, Melick N, Giansily-Blaizot M, Sallah S. Successful prophylaxis against intracranial hemorrhage using weekly administration of activated recombinant factor VII in a newborn with severe factor VII deficiency. J Thromb Haemost 2007; 5: 433-434.

2. Mariani G, Herrmann FH, Dolce A, et al; International Factor VII Deficiency Study Group. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005; 93: 481-487.

3. Williams WJ, Beutler E, Erslev AJ and Lichtman MA. Hematology (3rd ed), New York: McGraw-Hill, 1983.

4. Cooper DN, Millar DS, Wacey A, Banner DW, Tuddenham EG. Inherited factor VII deficiency: Molecular genetics and pathophysiology. Thromb Haemost 1997; 78: 151-160.

5. Ingerslev J, Kristensen HL. Clinical picture and treatment strategies in factor VII deficiency. Haemophilia 1998; 4: 689-696.

6. Charpiat B, Laporte S, Mismetti P, Debize G, Ducerf C. Perioperative pharmacokinetics of factor VII concentrate during liver surgery in a patient with congenital factor VII deficiency: An individual mathematical model. Blood Coagul Fibrinolysis 2002; 13: 457-460.

7. Wong WY, Huang WC, Miller R, McGinty K, Whisnant JK. Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency. Haemophilia 2000; 6: 50-54.

8. Mariani G, Testa MG, Di Paolantonio T, Molskov Bech R, Hedner U. Use of recombinant, activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sang 1999; 77: 131-136.

9. Mathew P, Young G. Recombinant factor VIIa in paediatric bleeding disorders -a 2006 review. Haemophilia 2006; 12: 457-472.

10. Brenner B, Wiis J. Experience with recombinantactivated factor VII in 30 patients with congenital factor VII deficiency. Hematology 2007; 12: 55-62.

11. Greisen G, Andreasen RB. Recombinant factor VIIa in preterm neonates with prolonged prothrombin time. Blood Coagul Fibrinolysis 2003; 14: 117-120.

12. Brady KM, Easley RB, Tobias JD. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage. Pediatr Anaesth 2006; 16: 1042-1046.

13. Olomu N, Kulkarni R, Manco-Johnson M. Treatment of severe pulmonary hemorrhage with activated recombinant factor VII (rFVIIa) in very low birth weight infants. J Perinatol 2002; 22: 672-674.

14. Karimi M, Shafieian R. Prophylactic effect of recombinant factor VIIa with congenital factor VII deficiency. Haemophilia 2008; 14: 851-852.

15. Veldman A, Josef J, Fischer D, Volk WR. A prospective pilot study of prophylactic treatment of preterm neonates with recombinant activated factor VII during the first 72 hours of life. Pediatr Crit Care Med 2006; 7: 34-39.